A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
4
Synergry Healthcare
Bradenton, Florida, United States
Florida Health Sciences Center/Tampa General Hospital/USF
Tampa, Florida, United States
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas, United States
UDL Clinical Research, LLC
Houston, Texas, United States
Treatment-Emergent Adverse Event Query
Incidence and severity of treatment-emergent adverse events
Time frame: Day 1 to Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Methodist Specialty and Transplant Hospital
San Antonio, Texas, United States
Bon Secours Liver Institute of Newport News
Richmond, Virginia, United States